A Problematic Biomarker Trial Design-Reference-Cited by-同舟云学术

A Problematic Biomarker Trial Design

Published:2021-07-21 Issue:2 Volume:114 Page:187-190
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Freidlin Boris¹^ORCID,Korn Edward L¹

Affiliation:

1. Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA

Abstract

Abstract Efficient biomarker-driven randomized clinical trials are a key tool for implementing precision oncology. A commonly used biomarker phase III design is focused on testing the treatment effect in biomarker-positive and overall study populations. This approach may result in recommending new treatments to biomarker-negative patients when these treatments have no benefit for these patients.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/advance-article-pdf/doi/10.1093/jnci/djab144/39767538/djab144.pdf

Reference14 articles.

1. Biomarker enrichment strategies: matching trial design to biomarker credentials;Freidlin;Nat Rev Clin Oncol,2014

2. Testing in a prespecified subgroup and the intent-to-treat population;Rothmann;Drug Inf J,2012

3. Marker Sequential Test (MaST) design;Freidlin;Clin Trials,2014

4. How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy;Fundytus;Ann Oncol,2021

5. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer;Johnston;J Clin Oncol,2009

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek;Clinical Trials;2023-04-24

2. Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials;JNCI: Journal of the National Cancer Institute;2022-11-30

3. Design and reporting of phase III oncology trials with prospective biomarker validation;JNCI: Journal of the National Cancer Institute;2022-11-30

4. ¹⁹ F Barcoding Enables Multiplex Detection of Biomarkers Associated with Organ Injury and Cancer;Angewandte Chemie International Edition;2022-10-17

5. ¹⁹ F Barcoding Enables Multiplex Detection of Biomarkers Associated with Organ Injury and Cancer;Angewandte Chemie;2022-10-14